PROGNOMIQ
PrognomiQ is a technology company that focuses on transforming early disease detection and treatment through multi-omics data. The company generates extensive proteomic, genomic, and metabolomic data to provide insights into complex diseases, aiming to improve patient outcomes. PrognomiQ's innovative approach facilitates the development of advanced test products that enhance the understanding and management of health conditions.
PROGNOMIQ
Industry:
Biopharma Biotechnology Health Care Medical Device
Founded:
2020-01-01
Address:
San Mateo, California, United States
Country:
United States
Website Url:
http://www.prognomiq.com
Total Employee:
11+
Status:
Active
Contact:
650 750-2447
Email Addresses:
[email protected]
Total Funding:
135 M USD
Technology used in webpage:
HSTS Google Maps Amazon CrUX Dataset CrUX Top 50m Amazon Virginia Region Ruby On Rails Token Envoy Amazon Oregon Region Pexels
Similar Organizations
Laparo
The team of software and hardware engineers who are pushing the boundaries of laparoscopy training and education.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
Pilot Biotechnology
Pilot Biotechnology is an industrial biotechnology company engaged in the development, production, and sales of health care products.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Current Advisors List
Current Employees Featured
Founder
Investors List
Invus
Invus investment in Series D - PrognomiQ
aMoon Fund
aMoon Fund investment in Series D - PrognomiQ
Catalio Capital Management
Catalio Capital Management investment in Series D - PrognomiQ
Seer
Seer investment in Series D - PrognomiQ
Bruker
Bruker investment in Series D - PrognomiQ
Emerson Collective
Emerson Collective investment in Venture Round - PrognomiQ
Fidelity
Fidelity investment in Venture Round - PrognomiQ
Maverick Ventures
Maverick Ventures investment in Venture Round - PrognomiQ
aMoon Fund
aMoon Fund investment in Venture Round - PrognomiQ
Bruker
Bruker investment in Venture Round - PrognomiQ
Official Site Inspections
http://www.prognomiq.com Semrush global rank: 7 M Semrush visits lastest month: 995
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "PrognomiQ"
PrognomiQ - Crunchbase Company Profile & Funding
PrognomiQ is a technology company that focuses on transforming early disease detection and treatment through multi-omics data. The company generates extensive proteomic, genomic, and metabolomic data to provide insights into …See details»
FACT SHEET - prognomiQ
About PrognomiQ . PrognomiQ. is a healthcare company focused on harnessing the power of multi-omics data to transform the detection and early treatment selection and monitoring of …See details»
PrognomIQ Company Profile 2024: Valuation, Funding …
Who are PrognomIQ’s investors? Seer, Catalio Capital Management, aMoon Fund, Bruker, and Emerson Collective are 5 of 11 investors who have invested in PrognomIQ. Data Transparency. Meet our data hygiene team. Discover how …See details»
PrognomiQ Inc - LinkedIn
PrognomiQ aims to generate proteomic information with high accuracy, scale and speed. This proteomic data will be complemented with genomic, metabolomic and other health information to deliver ...See details»
PrognomiQ Company Profile - Office Locations, Competitors
PrognomiQ is a company that develops test products that enable early disease detection and treatment. It generates proprietary proteomic data at unparalleled volumes and depth of …See details»
PrognomiQ - Contacts, Employees, Board Members, Advisors
Organization. PrognomiQ . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. ... PrognomiQ has 2 board members and …See details»
PrognomiQ Announces $34 Million Series D Financing to Advance ...
Nov 5, 2024 PrognomiQ – New Appointment of Isaac Ro to Board of Directors Brings Broad Diagnostic Industry & Operations Experience to Company –. SAN MATEO, Calif., Nov. 05, …See details»
PrognomiQ Announces $46 Million Financing to Advance …
Mar 15, 2022 About PrognomiQ Founded in 2020, PrognomiQ is a healthcare company pursuing the development and commercialization of multi-omics human tests for cancer and other …See details»
PrognomiQ Announces $34 Million Series D Financing to Advance ...
Nov 5, 2024 About PrognomiQ Founded in 2020, PrognomiQ is a healthcare company pursuing the development and commercialization of multi-omics human tests for cancer and other …See details»
PrognomiQ Announces $34 Million Series D Financing to Advance ...
San Mateo, Calif. – November 5, 2024 – PrognomiQ – a healthcare company focused on harnessing the power of multi-omics data to transform the detection and early treatment …See details»
PrognomiQ's Multi-omics Liquid Biopsy Platform Demonstrates …
Jan 9, 2023 PrognomiQ uses leading-edge proteomics technologies, in addition to metabolomics and genomics technologies, to develop multi-omics products to improve human health. For …See details»
PrognomiQ's Latest Research Demonstrates the Potential of its …
Jan 8, 2024 PrognomiQ – a healthcare company focused on harnessing the power of multi-omics data to transform the early detection, treatment selection and recurrence monitoring of …See details»
PrognomiQ's Latest Research Demonstrates the Potential of its …
Jan 8, 2024 About PrognomiQ: Founded in 2020, PrognomiQ is a healthcare company pursuing the development of multi-omics human tests for cancer and other complex diseases. …See details»
PrognomiQ Announces $46 Million Financing to Advance …
Mar 15, 2022 About PrognomiQ Founded in 2020, PrognomiQ is a healthcare company pursuing the development and commercialization of multi-omics human tests for cancer and other …See details»
NEWS & RESOURCES - prognomiQ
PrognomiQ Announces $34 Million Series D Financing to Advance Development of Early Detection Test for Lung Cancer with Multi-omics Platform. Read More. 01/08/2024. …See details»
PrognomiQ's Multi-omics Liquid Biopsy Platform Demonstrates …
Jan 9, 2023 PrognomiQ uses leading-edge proteomics technologies, in addition to metabolomics and genomics technologies, to develop multi-omics products to improve human health. For …See details»
PrognomiQ Aims to Launch Multiomic Lung Cancer Screening
Apr 19, 2024 NEW YORK – PrognomiQ, a spinoff of proteomics technology firm Seer, hopes to launch its first test, a blood-based lung cancer screening assay, within a year after completing …See details»
$46 Million Financing to Advance Multi-omics Product Pipeline
Nov 5, 2024 PrognomiQ Announces $46 Million Financing to Advance Development of its Multi-omics Product Pipeline for Early Detection and Treatment of Cancer PrognomiQ – a …See details»
Promising Results | Largest, Deep Multi-omics Study To Date
Jan 8, 2024 PrognomiQ’s Latest Research Demonstrates the Potential of its Multi-omics Liquid Biopsy Platform in Early-Stage Detection of Lung Cancer. San Mateo, Calif. – January 8, 2024 …See details»